Two Research Articles Cite HemogloBind™ To Reduce Analytical Interferences

By: Biotech Support Group
 
MONMOUTH JUNCTION, N.J. - Dec. 1, 2018 - PRLog -- Biotech Support Group reports on two research articles describing the describing the simplicity and efficiency of their hemoglobin depletion technology for improving analyte measurements from red cell lysates and liver perfusion fluids. The citations are:

O'Connell, Grant C., et al. "Monocyte-lymphocyte cross-communication via soluble CD163 directly links innate immune system activation and adaptive immune system suppression following ischemic stroke (https://www.nature.com/articles/s41598-017-13291-6)." Scientific reports 7.1 (2017): 12940, and

Laing, Richard W., et al. "The use of an acellular oxygen carrier in a human liver model of normothermic machine perfusion (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656179/)." Transplantation 101.11 (2017): 2746.

In the first reference, the purpose of this study was to investigate CD163 as a possible effector of stroke-induced adaptive immune system suppression as this is a scavenger receptor expressed on innate immune cell populations. A soluble peptide with lympho-inhibitory properties can be shed from the plasma membrane via the metalloprotease ADAM17. The article states "Total hemocyte fractions were thawed, mixed with NP-40 lysis buffer (Thermo Fisher) at a 1 to 1 ratio, and depleted of hemoglobin via the HemogloBind hemoglobin removal kit (Biotech Support Group, Monmouth Junction, NJ)… ADAM17 activity was measured in 200 ug of total hemocyte lysate". The authors provide novel evidence that the innate immune system employs protective mechanisms aimed at mitigating the risk of post-stroke autoimmune complications, and that CD163 is a key mediator of this phenomenon.

In the second reference, the authors present the first experience of using an acellular hemoglobin-based oxygen carrier (HBOC) Hemopure in a human model of Normothermic machine perfusion of the liver (NMP-L). This is a novel technique that preserves liver grafts under near-physiological conditions while maintaining their normal metabolic activity. The article states "All perfusates underwent haemoglobin depletion using Hemoglobind (BioTech Support Group LLC, Monmouth Junction, NJ) as per the manufacturer's instructions, except using a 1:8 ratio to ensure removal of all free haemoglobin. Perfusate levels of 8-OH-dG were quantified using a competitive ELISA (Abcam) as per the manufacturers protocol" .The authors conclusion is that Hemopure can be used as an alternative oxygen carrier to packed red cells in NMP-L perfusion fluid.

"The large amount of hemoglobin in samples of this type presents a special challenge for quantitative analysis. These articles demonstrate yet again that HemogloBind™ can reduce the interference associated with large concentrations of hemoglobin, without compromising the recovery and analysis of the protein(s) of interest." states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on HemogloBind™ (http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin...)

Click here for more information on all of our Hemoglobin Removal products (https://www.biotechsupportgroup.com/Articles.asp?ID=452)

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to  http://www.biotechsupportgroup.com

Contact:
Matthew Kuruc
732-274-2866
mkuruc@biotechsupportgroup.com

Contact
Biotech Support Group LLC
***@biotechsupportgroup.com
7322742866
End
Source:Biotech Support Group
Email:***@biotechsupportgroup.com Email Verified
Tags:Hemoglobin
Industry:Biotech
Location:Monmouth Junction - New Jersey - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Biotech Support Group LLC News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share